论文部分内容阅读
目的对恩替卡韦治疗慢性乙型肝炎的疗效进行分析,为临床提供依据。方法选取2012年10月至2015年12月在本院就诊并接受治疗的慢性乙型肝炎患者50例,按照随机的原则分为治疗组和对照组,治疗组27例予以恩替卡韦抗病毒治疗,对照组23例予以传统护肝综合治疗。结果比较2组在治疗第12周,第24周,第48周时病毒学应答、血清学应答、生化学应答及安全性指标等方面的差异,发现在HBV-DNA阴转率、HBe Ag阴转率、ALT复常率2组之间的差异具有统计学意义。治疗组和对照组均未发生任何严重不良事件。结论恩替卡韦是治疗慢性乙型肝炎的有效药物,可明显降低血清HBV-DNA水平,提高血清HBV-DNA完全抑制比例,改善肝功能,延缓病情的进一步发展,提高患者的生存质量及生存期,部分患者甚至可以达到治愈的目的,且耐药率低,能提高患者的满意度,无严重不良反应,安全性较高,在临床上值得广泛运用。
Objective To analyze the curative effect of entecavir in the treatment of chronic hepatitis B and provide the basis for clinical study. Methods 50 patients with chronic hepatitis B who were treated and treated in our hospital from October 2012 to December 2015 were randomly divided into treatment group and control group, and 27 patients in the treatment group were treated with antiviral therapy of entecavir. The control group Group 23 cases were treated with traditional liver protection. Results The differences of virological response, serological response, biochemical response and safety index between the two groups at the 12th week, the 24th week and the 48th week were compared. It was found that in the HBV-DNA negative rate, HBeAg negative Transfer rate, ALT normalization rate difference between the two groups was statistically significant. No serious adverse events occurred in the treatment group and the control group. Conclusion Entecavir is an effective drug for the treatment of chronic hepatitis B, which can significantly reduce the level of serum HBV-DNA, increase the complete inhibition ratio of serum HBV-DNA, improve the liver function, delay the further development of the disease, improve the quality of life and survival of patients, Patients can even achieve the purpose of cure, and the low rate of resistance, can improve patient satisfaction, no serious adverse reactions, high safety, it is widely used in clinical.